Search results for: v

2019 Human Amyloid Imaging Conference Participation

APRINOIA will present the latest clinical trial results for its lead Tau PET Imaging Tracer APN-1607 (PM-PBB3) at the Human Amyloid Imaging (HAI) Conference in Miami, USA in January 2019. We will deliver a total of 10 presentations with our partners.

APRINOIA Licenses Tau PET Imaging Tracer APN-1607 to Celgene

APRINOIA Therapeutics announced today that it has entered into a non-exclusive licensing agreement with Celgene Corporation. The agreement authorizes Celgene to use APN-1607, a novel investigational [18F]-labeled positron emission tomography (PET) imaging tracer, to support patient selection and efficacy evaluation in its global clinical trials.

APRINOIA tackles Tau

​Aprinoia Therapeutics Inc. is developing a pipeline targeting tauopathies that includes diagnostic imaging tracers, mAbs specific to pathologic tau and small molecules that bind to tau rather than dissociate tau aggregates.
“We are going to develop imaging biomarkers for all the therapeutic targets first to see those targets, and then find therapies,” CEO Ming-Kuei Jang told BioCentury.

APRINOIA Closed US$11.1 Million Series B Financing

APRINOIA has completed its US$11.1 million Series B round. The Series B round was led by KTB Network (Korea) and DCI Partners (Japan), along with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). The proceeds of the funding will be used to finance preclinical and clinical development for APRINOIA’s tau centric programs.